Rezolute Inc. (NASDAQ:RZLT) shares are up on Tuesday as the company is providing an update on its congenital hyperinsulinism program following a meeting with the FDA.

In a recent update, Rezolute shared insights from its March 17 meeting with the FDA regarding its Phase 3 sunRIZE trial for ersodetug, aimed at treating congenital hyperinsulinism.

FDA Meeting Highlights Mixed Efficacy Signals In SunRIZE Trial

The company reported that while the primary endpoint was not statistically significant, there were clinically meaningful improvements in hypoglycemia events as measured by continuous glucose monitoring.

The FDA acknowledged the challenges posed by behavioral factors in clinical trials, emphasizing the need for well-controlled studies.

Rezolute is expected to submit further study reports for independent evaluation, which could lead to a marketing application for ersodetug later this year.

The agency and the company then discussed summary outcomes from various CGM-based glycemic endpoints and preliminary observations from the OLE. 

Regulatory Path Hinges On Additional Data Submission And Independent Review

As a next step for the program, the FDA encouraged Rezolute to submit study reports and analysis datasets for the agency’s independent evaluation. 

Following that review, Rezolute believes that a determination may be made whether there is sufficient evidence to support the submission of a marketing application for sunRIZE or if additional information is required. The company expects to have an update on the program in the second half of 2026.

Rezolute Technical Analysis

The stock is currently trading 13.9% below its 20-day simple moving average (SMA) and 48.5% below its 100-day SMA, indicating a bearish trend in the short to medium term.

Shares have decreased by 15.84% over the past 12 months and are positioned closer to their 52-week lows than highs.

The RSI is at 35.46, which is considered neutral territory, while the MACD shows a value of -0.2377, below its signal line at -0.1705, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum for Rezolute, indicating that while the stock is not oversold, it is still facing downward pressure.

  • Key Resistance: $3.00
  • Key Support: $2.00

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $10.67. Recent analyst moves include:

  • Wedbush: Neutral (Raises Target to $2.00) (Jan. 8)
  • BTIG: Buy (Maintains Target to $5.00) (Jan. 8)
  • Guggenheim: Buy (Lowers Target to $6.00) (Dec. 12, 2025)

RZLT Stock Price Activity: Rezolute shares were up 7.29% at $2.58 at the time of publication on Tuesday, according to Benzinga Pro data.

Image via Shutterstock